In 2024, several research and pharmacological advancements were made for tardive dyskinesia, a movement disorder caused by dopamine-blocking medications. Below are some of the highlights of the year.

Accurate and early diagnosis of tardive dyskinesia (TD), a serious movement disorder typically caused by exposure to antipsychotic medications, is imperative for long-term management. "Keeping an eye ...

Some studies suggest vitamin E may help ease symptoms of tardive dyskinesia — but how strong is the evidence, and what does it really tell us? Note: The U.S. Food and Drug Administration (FDA) does ...

Neurocrine Biosciences, maker of the first drug approved by the FDA to treat tardive dyskinesia, continues to throw its weight behind efforts to improve screening, monitoring and general awareness of ...

Please provide your email address to receive an email when new articles are posted on . Both percent-predicted FEV 1 and FVC in primary ciliary dyskinesia improved with the addition of idrevloride to ...

The findings of this study align with prior research that suggests lower effective doses of clozapine are required for patients of Indian descent compared to Western populations. Switching patients of ...

Credit: FDA. The new sprinkle formulation is intended to be opened for sprinkling on soft foods prior to administration. The Food and Drug Administration (FDA) has accepted for review the New Drug ...

Significantly increased risk for tardive dyskinesia seen with doses of greater than 75mg/day at last prescription and as maximum dose. HealthDay News — Antipsychotics at doses greater than 75mg/day ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed its initial recommendation to not consider deutetrabenazine as a new active substance. In June this ...